• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023
Recommend to a Colleague print
 

Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides

Download the slide deck

TOPICS: Library, MS
Recommend to a Colleague

Related Posts

  • Treatment discontinuation in MS: the DOT-MS trial
    May 5, 2025
  • CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS
    April 25, 2025
  • AAN 2025 – report on fluid biomarkers in MS
    April 22, 2025
  • Ofatumumab – new data on efficacy and safety
    April 14, 2025
  • AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 9, 2025
    April 9, 2025
Go back to home page

Browse by Topic

  • EPILEPSY (36)
  • MS (412)
  • CLINICAL CASES IN MS (15)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • McDonald criteria 2024: what changes can we expect? posted on January 30, 2024
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions